In-hospital Mortality of Patients with Atrial Arrhythmias: Insights from the German-wide Helios Hospital Network of 161 502 Patients and 34 025 Arrhythmia-related Procedures
Overview
Authors
Affiliations
Aims: Atrial fibrillation (AFib) and atrial flutter (AFlut) are common arrhythmias with increased use of invasive procedures. A steady re-evaluation of relevant safety endpoints is recommended and both quality management and pay-for-performance programs are evolving. Therefore, the aims of this study were (i) to investigate and report overall in-hospital mortality and mortality of invasive arrhythmia-related procedures and (ii) to identify mortality predictors in a German-wide hospital network.
Methods And Results: Administrative data provided by 78 Helios hospitals between 2010 and 2017 were examined using International Statistical Classification of Diseases and Related Health Problems- and Operations and Procedures-codes to identify patients with AFib or AFlut as main discharge diagnosis or secondary diagnosis combined with invasive arrhythmia-related interventions. In 161 502 patients, in-hospital mortality was 0.6% with a significant decrease from 0.75% to 0.5% (P < 0.01) during the observational period. In multivariable analysis, age [odds ratio (OR) 2.69, 95% confidence interval (CI) 2.36-3.05; P < 0.01], high centre volume (OR 0.57, 95% CI 0.50-0.65; P < 0.01), emergency hospital admission (OR 1.57, 95% CI 1.38-1.79; P < 0.01), and Charlson Comorbidity Index (CCI, OR 4.95, 95% CI 4.50-5.44; P < 0.01) were found as independent predictors of in-hospital mortality. Mortality rates were 0.05% for left atrial catheter ablation (CA, n = 21 744), 0.3% for right atrial CA (n = 9972), and 0.56% for implantation of a left atrial appendage occluder (n = 2309), respectively.
Conclusion: We analysed for the first time in-hospital mortality rates of patients with atrial arrhythmias in a German-wide, multi-centre administrative dataset. This allows feasible, comparable, and up-to-date performance measurement of clinically important endpoints in a real-world setting which may contribute to quality management programs and towards value-based healthcare.
Yu Q, Zhao L, Tang T, Xin Z, Feng L, Rao X BMC Cardiovasc Disord. 2025; 25(1):49.
PMID: 39863875 PMC: 11762119. DOI: 10.1186/s12872-024-04449-y.
Cheng H, Chang K, Wu B, Teo M, Hung W, Wu H Infect Drug Resist. 2025; 18():151-160.
PMID: 39803308 PMC: 11725234. DOI: 10.2147/IDR.S479896.
Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Arrhythm. 2024; 40(6):1217-1354.
PMID: 39669937 PMC: 11632303. DOI: 10.1002/joa3.13082.
Medei E, Moll-Bernardes R, Pinheiro M, Sousa A, Abufaiad B, Feldman A Arq Bras Cardiol. 2024; 121(9):e20240310.
PMID: 39352189 PMC: 11495564. DOI: 10.36660/abc.20240310.
Pan Z, Zeng J, Li T, Hu F, Cai X, Wang X BMC Geriatr. 2024; 24(1):413.
PMID: 38730354 PMC: 11084079. DOI: 10.1186/s12877-024-05015-z.